- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
Population: General population
Individuals who do not belong to a defined subgroup with specific characteristics, representing the broader population
- General population
- Infants (<1 year)
- Hospital
- Primary care
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Primary care
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Emergency department
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Emergency department
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- General population
- Infants (<1 year)
- Hospital
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Community
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Emergency department
- Respiratory syncytial virus